NEWS

WIRES

OTHER

Vicor Technologies to Present at Noble Financial 2010 Equity Conference

Vicor Technologies, Inc. (OTCBB: VCRT) today announced that David H. Fater, its President, Chief Executive Officer, and Chairman, will be presenting at ONTRACK 2010, Noble Financial's Sixth Annual Equity Conference, June 7-8, 2010, at the Hard Rock Hotel in Hollywood, FL. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor develops diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

Mr. Fater will describe Vicor's technology, product commercialization status, and future strategy at 2:00pm EDT on Monday, June 7, in room 3: Piquet. Mr. Fater and other members of the Company's senior management team will be available for one-on-one meetings during the two days of the conference.

The complete presentation will be webcast live from Vicor's website -- www.vicortech.com -- and from the Noble Financial websites www.ontrack10.com or www.nobleresearch.com. Vicor recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. Attendees require the SilverLight viewer (a free download from presentation link) to participate. The complete webcast will be archived and remain available at Vicor's website.

About Noble Financial
Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service investment banking boutique focused on small-cap, emerging growth companies. The company has offices in New York, Boston, St Louis, and Boca Raton.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients with elevated risk of cardiac death, including sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA marketing clearance of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™(Cardiac Analyzer) for identification of patients at elevated risk of cardiac death; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-09